Cochrane · systematic review · CD004887
Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases
Martí‐Carvajal, AJ, Karakitsiou, DE, Salanti, G · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 60%High 2 · 40%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Recombinant human factor VII activated compared to placebo for upper gastrointestinal bleeding and liver diseases.
Population: patients with upper gastrointestinal bleeding and liver diseases.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality within 5 days Recombinant human factor VII activated vs placebo | RR 0.95 [0.36, 2.5] | 2 studies · 493 participants | Moderate Downgraded: inconsistency |
Mortality within 42 days Recombinant human factor VII activated vs placebo | RR 1.01 [0.55, 1.87] | 2 studies · 491 participants | Moderate Downgraded: inconsistency |
Adverse events (overall incidence) Recombinant human factor VII activated vs placebo | RR 0.94 [0.84, 1.04] | 2 studies · 507 participants | High |
Serious adverse events by total adverse events Recombinant human factor VII activated vs placebo | RR 0.9 [0.73, 1.09] | 2 studies · 1043 participants | High |
Thromboembolic events by patients Recombinant human factor VII activated vs placebo | RR 0.8 [0.4, 1.6] | 2 studies · 507 participants | Moderate Downgraded: inconsistency |